Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Development programs in this segment also include expansion of synthetic hypericin (SGX302) into psoriasis and dusquetide (SGX942 and SGX945) for the treatment of inflammatory diseases. We show 33 historical shares outstanding datapoints in our SNGX shares outstanding history coverage, used to compute SNGX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SNGX market cap history over the course of time is important for investors
interested in comparing SNGX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SNGX versus a peer is one thing; comparing
SNGX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SNGX can fluctuate over the course of history.
With this page we aim to empower investors researching SNGX by allowing them to research the SNGX market cap history. |
Free SNGX Email Alerts:
Video: The Importance of Market Cap
